Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Endometrial Cancer
DRUG: retifanlimab|DRUG: epacadostat|DRUG: pemigatinib|DRUG: INCAGN02385|DRUG: INCAGN02390
Group A - Objective Response Rate, Defined as the proportion of participants having a CR or PR according to RECIST v1.1, as assessed by Independent Central Review committee, up to 2.5 years
Group A -Duration of Response, Defined as the time from the first documented objective response (CR or PR) according to RECIST v1.1 (as determined by ICR) until disease progression or death due to any cause., up to 2.5 years|Group A - Disease Control Rate, Defined as the proportion of participants with CR, PR, or SD (as determined by ICR) as best response., up to 2.5 years|Group A - Overall Survival, Defined as the time from the first dose of study treatment until death due to any cause., up to 3.5 years|Group A - Progression Free Survival, Defined as the time from the first dose of study treatment until disease progression (as determined by ICR) or death due to any cause., up to 3.5 years|Group B -Duration of Response, Defined as the time from the first documented objective response (CR or PR) according to RECIST v1.1 (as determined by ICR) until disease progression or death due to any cause., up to 2.5 years|Group B - Disease Control Rate, Defined as the proportion of participants with CR, PR, or SD (as determined by ICR) as best response., up to 2.5 years|Group B - Overall Survival, Defined as the time from the first dose of study treatment until death due to any cause., up to 3.5 years|Groups B - Objective Response Rate, Defined as the proportion of participants having a CR or PR according to RECIST v1.1, as assessed by Independent Central Review committee, up to 2 years|Group B - Progression Free Survival, Defined as the time from the first dose of study treatment until disease progression (as determined by ICR) or death due to any cause., up to 3.5 years|Groups C, D, E and F - Objective Response Rate, Defined as the proportion of participants having a CR or PR according to RECIST v1.1, as assessed by Independent Central Review committee, up to 2 years|Number of Treatment-Related Adverse Events, Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment., up to 4 years
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.